The effect of evidence-based medication use on long-term survival in patients hospitalised for heart failure in Western Australia
- PMID: 20230346
- DOI: 10.5694/j.1326-5377.2010.tb03528.x
The effect of evidence-based medication use on long-term survival in patients hospitalised for heart failure in Western Australia
Abstract
Objectives: To examine trends and predictors of prescription medications on discharge after first (index) hospitalisation for heart failure (HF), and the effect on all-cause mortality of evidence-based therapy.
Design: A retrospective multicentre cohort study, with medical record review.
Setting: Three tertiary-care hospitals in Perth, Western Australia.
Patients: WA Hospital Morbidity Data were used to identify a random sample of 1006 patients with an index admission to hospital for HF between 1996 and 2006.
Main outcome measures: Proportion of patients prescribed evidence-based therapy for HF on discharge from hospital; and 1-year all-cause mortality.
Results: Among 944 patients surviving to hospital discharge, the prescription rate of angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARBs) (74.3%) and loop diuretics (85.5%) remained high over the study period, whereas that of beta-blockers and spironolactone increased (10.5% to 51.3% and 1.4% to 23.3%, respectively), and digoxin prescription decreased (38.1% to 20.7%). The temporal trends in use of beta-blockers, spironolactone and digoxin were in line with clinical trial evidence. Age > or = 75 years was a significant, negative predictor of beta-blocker and spironolactone prescription. In-hospital echocardiography, performed in 53% of patients, was associated with a significantly greater likelihood of treatment with ACE inhibitors/ARBs, beta-blockers and spironolactone. Both ACE inhibitors/ARBs and beta-blockers prescribed on discharge were associated with a lower adjusted hazard ratio (HR) for mortality at 1-year (HR, 0.71; P = 0.003; and HR, 0.68; P = 0.002, respectively).
Conclusion: ACE inhibitors/ARBs and beta-blockers, prescribed during initial hospitalisation for HF, are associated with improved long-term survival. Therapy became more evidence based over the study period, but echocardiography, an important predictor of evidence-based therapy, was underutilised.
Similar articles
-
Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study.Lancet Glob Health. 2018 Sep;6(9):e1008-e1018. doi: 10.1016/S2214-109X(18)30306-1. Lancet Glob Health. 2018. PMID: 30103979
-
Effects of ACE inhibitors or beta-blockers in patients treated with the fixed-dose combination of isosorbide dinitrate/hydralazine in the African-American Heart Failure Trial.Am J Cardiovasc Drugs. 2007;7(5):373-80. doi: 10.2165/00129784-200707050-00007. Am J Cardiovasc Drugs. 2007. PMID: 18041162 Clinical Trial.
-
Comparison of one-year outcome (death and rehospitalization) in hospitalized heart failure patients with left ventricular ejection fraction >50% versus those with ejection fraction <50%.Am J Cardiol. 2008 Jul 1;102(1):79-83. doi: 10.1016/j.amjcard.2008.02.102. Epub 2008 May 9. Am J Cardiol. 2008. PMID: 18572040
-
Postponement of Death by Pharmacological Heart Failure Treatment: A Meta-Analysis of Randomized Clinical Trials.Am J Med. 2020 Jun;133(6):e280-e289. doi: 10.1016/j.amjmed.2019.11.015. Epub 2020 Mar 13. Am J Med. 2020. PMID: 32173347
-
[Heart failure - up to date].Praxis (Bern 1994). 2013 Aug 21;102(17):1053-60. doi: 10.1024/1661-8157/a001381. Praxis (Bern 1994). 2013. PMID: 23965718 Review. German.
Cited by
-
Rural-urban differentials in 30-day and 1-year mortality following first-ever heart failure hospitalisation in Western Australia: a population-based study using data linkage.BMJ Open. 2014 May 2;4(5):e004724. doi: 10.1136/bmjopen-2013-004724. BMJ Open. 2014. PMID: 24793254 Free PMC article.
-
A cohort study: temporal trends in prevalence of antecedents, comorbidities and mortality in Aboriginal and non-Aboriginal Australians with first heart failure hospitalization, 2000-2009.Int J Equity Health. 2015 Aug 12;14:66. doi: 10.1186/s12939-015-0197-4. Int J Equity Health. 2015. PMID: 26265218 Free PMC article.
-
Phase 4 Studies in Heart Failure - What is Done and What is Needed?Curr Cardiol Rev. 2016;12(3):216-30. doi: 10.2174/1573403x12666160606121458. Curr Cardiol Rev. 2016. PMID: 27280303 Free PMC article. Review.
-
Association is not causation: treatment effects cannot be estimated from observational data in heart failure.Eur Heart J. 2018 Oct 1;39(37):3417-3438. doi: 10.1093/eurheartj/ehy407. Eur Heart J. 2018. PMID: 30085087 Free PMC article.
-
Heart Failure in Minority Populations - Impediments to Optimal Treatment in Australian Aborigines.Curr Cardiol Rev. 2016;12(3):166-79. doi: 10.2174/1573403x12666160606115034. Curr Cardiol Rev. 2016. PMID: 27280307 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous